The correlation of HPV16 and HPV18 with local vaginal immunity after the treatment of cervical intraepithelial neoplasia

被引:2
|
作者
Mu, Lin [1 ]
Miao, Jing-Rui [1 ]
Song, Jing-Hui [1 ]
机构
[1] Inner Mongolia Med Univ, Dept Obstet & Gynecol, Affiliated Hosp, 1 North Tongdao St, Inner Mongolia 100059, Peoples R China
基金
中国国家自然科学基金;
关键词
Cervical intraepithelial neoplasia (CIN); cervical squamous cell carcinoma; HPV; 16; 18; vaginal local immune factor; PROGRESSION; DNA;
D O I
10.21037/tcr-19-2955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This study aimed to investigate the correlation between the level of HPV16 and HPV18 in patients with cervical lesions and the local vaginal immunity after receiving treatment with different degrees of cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma (CSCC). Methods: One hundred and thirty-six patients with LSIL (grade 1 CIN or CIN 1), 263 patients with HSIL (grade 2 and 3 CIN or CIN 2 and 3), and 33 patients with CSCC pathologically confirmed between November 2012 and September 2016 were assigned to the test group and 100 healthy women in the same period were assigned to the control group. ELISA was used to determine the levels of SIgA, IgG, IL-2, and IL-10 and the IL-2/IL-10 ratio in vaginal lavage fluid in the test group (before treatment and 3, 6, and 12 months after treatment) and the control group, respectively. Gene chip technology was adopted to test the HPV infection in the test group (before treatment and 3, 6, and 12 months after treatment) and the control group, respectively. Results: The results showed that the levels of SIgA, IgG, and IL-10 were positively correlated with the degree of cervical lesions and IL-2/IL-10 was negatively correlated with the degree in all patients before treatment. The levels of SIgA, IgG, and IL-10 were positively correlated with the degree of cervical lesions and IL-2/IL-10 was negatively correlated with the degree in HPV16 and HPV18-infected patients before receiving the treatment. Conclusions: The recovery after the treatment of HPV infection is time-dependent and the immune system of patients with CIN starts to recover in the 6th month after treatment, early intervention is not recommended. However, the immune system is approximately in a normal sate at 12 months after treatment, at which time the efficacy can be evaluated, and clinical intervention can be initiated if necessary. The level of local immune factors in the vagina can be monitored to determine the progression and prognosis of patients' cervical lesions.
引用
收藏
页码:4212 / 4223
页数:12
相关论文
共 50 条
  • [41] The Significance Of Human Papillomavirus (HPV) After Treatment For Cervical Intraepithelial Neoplasia (CIN)
    Wyse, A.
    Byrne, P.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S24 - S24
  • [42] HPV16与HPV18假病毒核酸标准物质定值研究
    李会杰
    陈桂芳
    董莲华
    杨佳怡
    杨靖亚
    计量学报, 2023, 44 (03) : 384 - 391
  • [43] HPV16 and HPV18 type-specific APOBEC3 and integration profiles in different diagnostic categories of cervical samples
    Lagstrom, Sonja
    Lovestad, Alexander Hesselberg
    Umu, Sinan Ugur
    Ambur, Ole Herman
    Nygard, Mari
    Rounge, Trine B.
    Christiansen, Irene Kraus
    TUMOUR VIRUS RESEARCH, 2021, 12
  • [44] DETECTION OF HUMAN PAPILLOMAVIRUS USING THE POLYMERASE CHAIN-REACTION AND TYPING FOR HPV16 AND HPV18 IN THE CERVICAL SMEARS OF GREEK WOMEN
    LAMBROPOULOS, AF
    AGORASTOS, T
    FRANGOULIDES, E
    KARAHALIOU, R
    BONTIS, J
    DOZIVASSILIADES, I
    JOURNAL OF MEDICAL VIROLOGY, 1994, 43 (03) : 228 - 230
  • [45] Lifestyle factors associated with HPV16 and HPV18 infection in 5000 UK women with low-grade abnormal cervical smears
    Cotton, S. C.
    Sharp, L.
    Masson, L. F.
    Seth, R.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2006, 21 : 138 - 138
  • [46] HIGH-RISK HPV testing as the primary screening method in an organized regional screening program for cervical cancer: the value of HPV16 and HPV18 genotyping?
    Kares, Saara
    Veijalainen, Olga
    Kholova, Ivana
    Tirkkonen, Mika
    Vuento, Risto
    Huhtala, Heini
    Tuimala, Veronica
    Maenpaa, Johanna
    Kujala, Paula
    APMIS, 2019, 127 (11) : 710 - 716
  • [47] Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection
    Haupt, Richard M.
    Wheeler, Cosette M.
    Brown, Darron R.
    Garland, Suzanne M.
    Ferris, Daron G.
    Paavonen, Jorma A.
    Lehtinen, Matti O.
    Steben, Marc
    Joura, Elmar A.
    Giacoletti, Katherine E. D.
    Radley, David R.
    James, Margaret K.
    Saah, Alfred J.
    Sings, Heather L.
    INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (11) : 2632 - 2642
  • [48] How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands
    Coupe, Veerle M. H.
    de Melker, H. E.
    Snijders, Peter J. F.
    Meijer, Chris J. L. M.
    Berkhof, Johannes
    VACCINE, 2009, 27 (37) : 5111 - 5119
  • [49] HPV16/18+Oropharyngeal Carcinomas Are Associated with Enhanced Local Adaptive Immunity
    Dai, Q.
    Isayeva, T.
    Xu, J.
    Brandwein-Gensler, M.
    MODERN PATHOLOGY, 2012, 25 : 307A - 307A
  • [50] HPV16/18+Oropharyngeal Carcinomas Are Associated with Enhanced Local Adaptive Immunity
    Dai, Q.
    Isayeva, T.
    Xu, J.
    Brandwein-Gensler, M.
    LABORATORY INVESTIGATION, 2012, 92 : 307A - 307A